<DOC>
	<DOC>NCT00327834</DOC>
	<brief_summary>The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.</brief_summary>
	<brief_title>Atomoxetine in the Treatment of Binge Eating Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding and Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Subjects will meet the DSMIV criteria for a diagnosis of bingeeating disorder for at least the last 6 months In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization Have concurrent symptoms of bulimia nervosa or anorexia nervosa Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures Patients who are displaying clinically significant suicidality or homicidality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>